BioSpace News Archive

Amsterdam, the Netherlands – Royal Philips, a global leader in health technology, announced that it is one of the leading patent applicants at the European Patent Office.

XORTX Therapeutics Inc. is pleased to provide a summary of Company’s achievements in 2023 and objectives planned for 2024.

Telum Therapeutics is announcing the appointment of Subhendu Basu, PhD, as its new Chief Executive Officer.

Fennec Pharmaceuticals Inc. announced that the Company will release its full year and fourth quarter 2023 financial results before the opening of the U.S. financial markets on Thursday, March 21, 2024.

Crinetics Pharmaceuticals, Inc. announced positive topline results from PATHFNDR-2, the second of two Phase 3 studies evaluating the efficacy and safety of oral, once-daily investigational paltusotine for the treatment of acromegaly.

Opthea Limited announced it will host a virtual key opinion leader event on Wednesday, April 3, 2024, from 10:00 to 11:30 am ET, featuring presentations from global retina experts:

Portal Biotechnologies, Inc., a cell engineering platform company, announced a $5M pre-seed round led by Pear VC, with participation from Conscience VC and 10x Capital.

Solventum will host its inaugural Investor Day in New York City ahead of its planned spinoff from 3M.

CGI Federal Inc., a wholly-owned U.S. operating subsidiary of CGI Inc., has been awarded a single award, firm-fixed price contract by the Centers for Medicare & Medicaid Services to help improve access to Medicare for millions of beneficiaries by modernizing the agency’s Health Plan Management System.

Boehringer Ingelheim announced that the US FDA has approved SPEVIGO® injection for the treatment of generalized pustular psoriasis in adults and pediatric patients aged 12 and above weighing ≥40 kg.5 This approval follows the Chinese National Medical Products Administration’s recent approval of SPEVIGO® for the reduction of occurrence of generalized pustular psoriasis in adolescents from 12 years of age with a body weight ≥40 kg and adults.